Nasdaq
$14.41▼ 0.07%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $497.5MShares out 34.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 5d agoRegular26.10.20 04:41SCHEDULE 13D/AOwnership#●●●
DELCATH SYSTEMS, INC.
Rosalind Advisors, Inc. and Rosalind Master Fund L.P. have filed a Schedule 13D/A regarding their beneficial ownership of Delcath Systems, Inc. common stock. This filing formalizes the joint filing agreement between the reporting entities.…more
$14.41-0.07%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Regular26.10.15 03:444Ownership
DELCATH SYSTEMS, INC.
Rosalind Advisors, Inc. and associated individuals, as insiders and major shareholders of Delcath Systems, Inc., reported changes in their beneficial ownership as of October 13, 2026. This filing via SEC Form 4 details the specific adjustments in their equity holdings.…more
$14.41-0.07%vs prev closeView filingShare - 8.6Pre-market26.08.06 22:0910-QEarnings
DELCATH SYSTEMS, INC.
델캐스 시스템즈(Delcath Systems, Inc.)의 2026년 2분기 실적 보고에 따르면, 제품 매출은 2,913만 달러로 전년 동기 2,416만 달러 대비 증가했습니다. 2026년 6월 30일 기준 현금 및 현금성 자산은 4,752만 달러이며, 누적 결손금은 5억 2,725만 달러를 기록했습니다.…more
$14.41-0.07%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoAfter-hours26.10.20 05:04#●●●#●●●
Delcath Systems Presents Clinical Data at ESMO 2026
Delcath Systems presented data from its clinical development programs for liver cancer treatment at the ESMO Congress 2026. The company also highlighted a published analysis of its CHEMOSAT system for treating metastatic uveal melanoma.…more
$14.41-0.07%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga